VivoSim Labs, Inc. Nasdaq Vivs announced a seven-figure agreement with a top-10 global pharmaceutical company for its NAMkind human tissue testing services, prompting the company to forecast fiscal 2027 revenue growth ab
Why Is VivoSim Labs, Inc. (VIVS) Stock Up Today?
Updated Nov 20, 2026 5:04 AM ET · Prev Close $0.12
This stock has surged 143% today — an outlier single-session expansion. Parabolic moves frequently experience sharp mean-reversion pullbacks and wide bid-ask spreads.
Session Regime & Catalyst Assessment
68% Signal ConvictionVivoSim Labs, Inc. Advancing 142.92% on 22.06x Relative Volume
VivoSim Labs, Inc. (VIVS) is advancing 142.92% (+$0.17) to $0.29 on 22.06x average session volume. Relative to benchmarks, VIVS is outperforming the S&P 500 by +144.88%. 14-day RSI stands at 75.1, keeping momentum in a overbought regime.
VivoSim Labs, Inc. Nasdaq Vivs announced a seven-figure agreement with a top-10 global pharmaceutical company for its NAMkind human tissue testing services, prompting the company to forecast fiscal 2027 revenue growth ab
Price ($0.29) holds above both 20-day ($0.15) and 50-day ($0.18) moving averages.
Market & Sector Relative Strength
VIVS outperforming the S&P 500 by +144.88%Options Flow & Execution Desk
Recent VIVS Catalyst Headlines
Verified WireLiver and intestinal toxicology testing both grew in the quarter ended September 30, 2026. VivoSim anticipates that the customer will make NAMkind testing part of its regular flow of ongoing preclinical workSAN Diego, No
New data on 10 compounds pulled due to unforeseen liver tox highlight how VivoSim s models often easily catch clinical failure risk missed by animal models, using a complex approach that leverages several parameters stud
San Diego Ap San Diego Ap VivoSim Labs, Inc. VIVS on Thursday reported a loss of 475,000 in its fiscal second quarter.
1–3 Day Expected Range & Key Level
54% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $0.32 (session resistance) for directional breakout confirmation.
Technical Regime (VIVS)
MIXED MA TRENDRetail & Crowd Sentiment
Very BullishStockTwits is flooded with bullish sentiment towards $VIVS, with traders predicting price targets of $1 and beyond. The latest Yahoo Finance news reports VivoSim Labs securing a seven-figure pharmaceutical testing agreement, leading to increased revenue growth expectations for Fiscal 2027.
About VivoSim Labs, Inc.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology …
Get Instant VIVS Catalyst Alerts
Receive an email alert when VIVS triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversVIVS Session & Catalyst FAQ
Why is VIVS stock up today?
VivoSim Labs, Inc. (VIVS) is advancing 142.92% (+$0.17) to $0.29 on 22.06x average session volume. Relative to benchmarks, VIVS is outperforming the S&P 500 by +144.88%. 14-day RSI stands at 75.1, keeping momentum in a overbought regime.
Is VIVS stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 22.06x relative volume (high participation). Our multi-factor model currently rates VIVS as EXTENDED. Review full valuation, quality, and timing signals on the VIVS Buy or Sell Decision Brief →
What is VIVS's intrinsic value and expected trading range?
At $0.29, VIVS's modeled 1-to-3 session range is $0.27 – $0.31, with a key inflection level at $0.32 (session resistance). Compare current price against multi-year cash flow projections in the VIVS Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for VIVS?
RSI at 75.1 indicates overbought momentum — elevated pullback risk. VIVS trades at $0.29 relative to its 20-day SMA ($0.15) and 50-day SMA ($0.18), reflecting a mixed moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.